BlackRock Investment Management’s ImmunityBio IBRX Stock Holding History

BlackRock Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$364K	Hold	63,701	–	–	﹤0.01%	3127
2016 Q3	$496K	Sell	63,701 -142	-0.2%	-$1.06K	﹤0.01%	3054
2016 Q2	$397K	Buy	63,843 +40,625	+175%	+$315K	﹤0.01%	3162
2016 Q1	$191K	Buy	23,218 +1,409	+6%	+$13.3K	﹤0.01%	3168
2015 Q4	$378K	Buy	21,809 +1,615	+8%	+$24K	﹤0.01%	3098
2015 Q3	$231K	Buy	+20,194	New	+$441K	﹤0.01%	3225

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's IBRX Position: Q4 2016 in Review

BlackRock Investment Management held its ImmunityBio (IBRX) position steady in Q4 2016 at 63,701 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

BlackRock Investment Management first reported a position in IBRX in Q3 2015 and has held it in 6 quarters since. The position peaked at $496K in Q3 2016. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

BlackRock Investment Management held 63,701 shares of ImmunityBio worth $364K as of Q4 2016.
BlackRock Investment Management left its ImmunityBio share count unchanged in Q4 2016.
ImmunityBio made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3127 holding.
BlackRock Investment Management first reported a position in ImmunityBio in Q3 2015 and has held it in 6 quarters since.
BlackRock Investment Management's ImmunityBio position peaked at $496K in Q3 2016.
68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.